We are live on ! Find out more
ARKG icon

ARK Genomic Revolution ETF

93 hedge funds and large institutions have $142M invested in ARK Genomic Revolution ETF in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

38% more capital invested

Capital invested by funds: $103M → $142M (+$39.3M)

16% more funds holding

Funds holding: 8093 (+13)

3.25% more ownership

Funds ownership: 25.46%28.71% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
93
Holders Change
+13
Holders Change %
+16.25%
% of All Funds
1.83%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
33
Reduced
15
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AF
101
Advisornet Financial
Minnesota
-$44K -1,500 Closed
FAAS
102
First Allied Advisory Services
California
-$24K -800 Closed
AIC
103
Ameritas Investment Company
Nebraska
-$9K -288 Closed
FGAM
104
Financial Gravity Asset Management
Texas
-$7K -252 Closed

ARKG Hedge Fund Activity: Q4 2019 in Review

93 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2019, worth a combined $142M — up 38% from $103M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ARKG positions and 11 closed out — a net gain of 13 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was Wells Fargo, adding an estimated $8.66M. The largest seller was Raymond James & Associates, cutting an estimated $3.44M.

  • 93 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2019, up from 80 in Q3 2019.
  • Funds reported $142M of ARK Genomic Revolution ETF stock for Q4 2019, up 38% quarter-over-quarter.
  • 24 funds opened new ARK Genomic Revolution ETF positions in Q4 2019 and 11 closed out, a net change of +13 holders.
  • The largest ARK Genomic Revolution ETF buyer in Q4 2019 was Wells Fargo, an estimated $8.66M added.
  • The largest ARK Genomic Revolution ETF seller in Q4 2019 was Raymond James & Associates, an estimated $3.44M sold.

Based on aggregated 13F filings for Q4 2019.